A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

December 31, 2014

Conditions
Multiple Myeloma
Interventions
DRUG

Placebo, Velcade and dexamethasone

Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle

BIOLOGICAL

Siltuximab, Velcade and dexamethasone

Given in 21-day treatment cycles

Trial Locations (48)

Unknown

Iowa City

Boston

Toledo

Willow Grove

Milwaukee

Adelaide

Camperdown

Heidelberg

Parkville

Prahran

Edegem

Liège

Turnhout

Yvoir

Plovdiv

Sofia

Varna

Toronto

Hradec Králové

Liberec

Prague

Gandhinagar Guiarat

Apeldoorn

Deventer

Zwolle

Christchurch

Grafton

Nz 9 Takapuna Auckland

Palmerston North

Brzozów

Gdansk

Lodz

Opole

Wroclaw

Hwasun Gun

Seoul

Ankara

Bursa

Edirne

Cherkassy

Dnipro

Kharkiv

Khmelnitskiy

Kiev

Odesa

Simferopol

Vinnitsa

Nottingham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Centocor, Inc.

INDUSTRY